01 13Eliquis
02 2Eliquis
03 1Eliquis Alliance Revenues And Direct Sales
04 1Eliquis alliance revenues and direct sales
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 9,168
2019 Revenue in Millions : 7,929
Growth (%) : 16
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 4,949
2019 Revenue in Millions : 4,220
Growth (%) : 17
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 10,762
2020 Revenue in Millions : 9,168
Growth (%) : 17
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 5,970
2020 Revenue in Millions : 4,949
Growth (%) : 21
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 6,480
2021 Revenue in Millions : 5,970
Growth (%) : 9
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 11,789
2021 Revenue in Millions : 10,762
Growth (%) : 10
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 12,206
2022 Revenue in Millions : 11,789
Growth (%) : 4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 6,747
2022 Revenue in Millions : 6,480
Growth (%) : 4
Main Therapeutic Indication : Anticoagulants
Currency : USD
2014 Revenue in Millions : 430.10%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anticoagulants
Currency : USD
2015 Revenue in Millions : 774
2014 Revenue in Millions : 1,860
Growth (%) : 140%
LOOKING FOR A SUPPLIER?